NLRP3 and colitis: There are reports that treatment with NLRP3 inhibitors can relieve colitis under DSS exposure (Daley et al., 2017), which might be caused by the local reduction of pro-inflammatory cytokines, including IL-1β, TNF-α, and IFN-γ (Kozma et al., 1994).